DOCSLIB.ORG

Stock Code: 6996

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Stock Code: 6996 (Incorporated in the Cayman Islands with limited liability) Stock Code: 6996 Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Bookrunner and Joint Lead Manager LifeGift_PPTUS Cover_Eng Cover Size: 210 x 280 mm / Open Size: 449.2 x 280 mm / Spine width: 29.2 mm IMPORTANT IMPORTANT: If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. Antengene Corporation Limited 德琪醫藥有限公司 (Incorporated in the Cayman Islands with limited liability) Global Offering Number of Offer Shares under : 154,153,500 Shares (subject to the the Global Offering Over-allotment Option) Number of Hong Kong Offer Shares : 15,416,000 Shares (subject to reallocation) Number of International Offer Shares : 138,737,500 Shares (subject to reallocation and the Over-allotment Option) Maximum Offer Price : HK$18.08 per Offer Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027% and Hong Kong Stock Exchange trading fee of 0.005% (payable in full on application in Hong Kong dollars, subject to refund) Nominal value : US$0.0001 per Share Stock code : 6996 Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers Joint Bookrunner and Joint Lead Manager Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this prospectus. A copy of this prospectus, having attached thereto the documents specified in the section headed “Documents Delivered to the Registrar of Companies and Available for Inspection” in this prospectus, has been registered with the Registrar of Companies in Hong Kong as required by section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong). The Securities and Futures Commission of Hong Kong and the Registrar of Companies in Hong Kong take no responsibility as to the contents of this prospectus or any other document referred to above. The Offer Price is expected to be fixed by agreement between the Joint Global Coordinators (on behalf of the Underwriters) and our Company on the Price Determination Date. The Price Determination Date is expected to be on or around Thursday, November 12, 2020 (Hong Kong time) and, in any event, not later than Thursday, November 19, 2020 (Hong Kong time). The Offer Price will not be more than HK$18.08 per Offer Share and is currently expected to be not less than HK$15.80 per Offer Share. Applicants for Hong Kong Offer Shares are required to pay, on application, the maximum Offer Price of HK$18.08 for each Hong Kong Offer Share together with a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK$18.08 per Offer Share. The Joint Global Coordinators (on behalf of the Underwriters) may, with our consent, reduce the number of Offer Shares and/or the indicative Offer Price range below that stated in this prospectus at any time prior to the morning of the last day for lodging applications under the Hong Kong Public Offering. In such case, notices of the reduction in the number of Offer Shares and/or the indicative Offer Price range will be published on the websites of the Stock Exchange at www.hkexnews.hk and our Company at www.antengene.com not later than the morning of the last day for lodging applications under the Hong Kong Public Offering. Prior to making an investment decision, prospective investors should consider carefully all of the information set out in this prospectus, including the risk factors set out in the section headed “Risk Factors” in this prospectus. The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for, and to procure subscribers for, the Hong Kong Offer Shares, are subject to termination by the Joint Global Coordinators (on behalf of the Underwriters) if certain events shall occur prior to 8:00 a.m. on the Listing Date. Such grounds are set out in the section headed “Underwriting” in this prospectus. It is important that you refer to that section for further details. The Offer Shares have not been and will not be registered under the U.S. Securities Act or any state securities law in the United States and may not be offered, sold, pledged or transferred within the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold (i) solely to QIBs pursuant to Rule 144A or another available exemption from registration under the U.S. Securities Act and (ii) outside the United States in offshore transactions in accordance with Regulation S. ATTENTION We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering. This prospectus is available at the website of the Hong Kong Stock Exchange at www.hkexnews.hk and our website at www.antengene.com. If you require a printed copy of this prospectus, you may download and print from the website addresses above. November 9, 2020 IMPORTANT IMPORTANT NOTICE TO INVESTORS: FULLY ELECTRONIC APPLICATION PROCESS We have adopted a fully electronic application process for the Hong Kong Public Offering. We will not provide printed copies of this prospectus or printed copies of any application forms to the public in relation to the Hong Kong Public Offering. This prospectus is available at the website of the Hong Kong Stock Exchange at www.hkexnews.hk under the “HKEXnews > New Listings > New Listing Information” section, and our website at www.antengene.com. If you require a printed copy of this prospectus, you may download and print from the website addresses above. To apply for the Hong Kong Offer Shares, you may: (1) apply online through the White Form eIPO service at www.eipo.com.hk; (2) apply through the CCASS EIPO service to electronically cause HKSCC Nominees to apply on your behalf, including by: i. instructing your broker or custodian who is a CCASS Clearing Participant or a CCASS Custodian Participant to give electronic application instructions via CCASS terminals to apply for the Hong Kong Offer Shares on your behalf; or ii. (if you are an existing CCASS Investor Participant) giving electronic application instructions through the CCASS Internet System (https://ip.ccass.com) or through the CCASS Phone System by calling +852 2979 7888 (using the procedures in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). HKSCC can also input electronic application instructions for CCASS Investor Participants through HKSCC’s Customer Service Centre at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong by completing an input request. If you have any question about the application for the Hong Kong Offer Shares, you may call the enquiry hotline of our Hong Kong Share Registrar and White Form eIPO Service Provider, Computershare Hong Kong Investor Services Limited, both at +852 2862 8690 on the following dates: Monday, 9 November 2020 — 9:00 a.m. to 9:00 p.m. Tuesday, 10 November 2020 — 9:00 a.m. to 9:00 p.m. Wednesday, 11 November 2020 — 9:00 a.m. to 9:00 p.m. Thursday, 12 November 2020 — 9:00 a.m. to 12:00 noon We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of this prospectus are identical to the printed prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance. If you are an intermediary, broker or agent, please remind your customers, clients or principals, as applicable, that this prospectus is available online at the website addresses above. Please refer to the section headed “How to Apply for Hong Kong Offer Shares” for further details of the procedures through which you can apply for the Hong Kong Offer Shares electronically. –i– IMPORTANT Your application must be for a minimum of 500 Hong Kong Offer Shares and in one of the numbers set out in the table. You are required to pay the amount next to the number you select. No. of Hong No. of Hong No. of Hong No. of Hong Kong Amount Kong Offer Amount Kong Offer Kong Offer Offer Shares payable on Shares payable on Shares Amount payable Shares applied Amount payable applied for application applied for application applied for on application for on application HK$ HK$ HK$ HK$ 500 9,131.09 10,000 182,621.92 200,000 3,652,438.43 4,000,000 73,048,768.64 1,000 18,262.19 15,000 273,932.88 300,000 5,478,657.65 4,500,000 82,179,864.72 1,500 27,393.29 20,000 365,243.84 400,000 7,304,876.86 5,000,000 91,310,960.80 2,000 36,524.39 25,000 456,554.80 500,000 9,131,096.08 6,000,000 109,573,152.96 2,500 45,655.48 30,000 547,865.76 600,000 10,957,315.30 7,000,000 127,835,345.12 3,000 54,786.57 35,000 639,176.73 700,000 12,783,534.51 7,708,000(1) 140,764,977.17 3,500 63,917.67 40,000 730,487.69 800,000 14,609,753.73 4,000 73,048.77 45,000 821,798.65 900,000 16,435,972.94 4,500 82,179.87 50,000 913,109.61 1,000,000 18,262,192.16 5,000 91,310.96 60,000 1,095,731.53 1,500,000 27,393,288.24 6,000 109,573.15 70,000 1,278,353.45 2,000,000 36,524,384.32 7,000 127,835.35 80,000 1,460,975.37 2,500,000 45,655,480.40 8,000 146,097.54 90,000 1,643,597.29 3,000,000 54,786,576.48 9,000 164,359.73 100,000 1,826,219.22 3,500,000 63,917,672.56 (1) Maximum number of Hong Kong Offer Shares you may apply for.
Load more

Recommended publications
  • Integrated Planning and Design of a Flood Relief Project for Sheung Wan Low-Lying Area
    INTEGRATED PLANNING AND DESIGN OF A FLOOD RELIEF PROJECT FOR SHEUNG WAN LOW-LYING AREA Mr. CHAN Kin-kwong, Chief Engineer Drainage Services Department, Hong Kong SAR Government Mr. TAM Kit-fan, Senior Engineer Drainage Services Department, Hong Kong SAR Government Ms. LEUNG Yuen-hei, Engineer Drainage Services Department, Hong Kong SAR Government Abstracts Sheung Wan is one of the earliest settlements in Hong Kong. A low-lying area of about 10 hectares in Sheung Wan, which is an important business and financial district and a reputable shopping place for dried seafood and swallow’s nest, is susceptible to flooding during heavy rainstorms when coincided with high tide. Before construction After completion Figure 1 – Overview of the site of Sheung Wan Stormwater Pumping Station from Shun Tak Centre 1 To relieve the flooding problems in this low-lying area of Sheung Wan, the Drainage Services Department has recently completed some drainage improvement works in 3 phases. Phase 1 includes construction of 660m of intercepting drains to intercept the stormwater runoff from the upland and divert it away to another drainage system. This reduces about 30% of the surface runoff from getting into the Sheung Wan low-lying area. Works started in March 2006 and was completed in June 2008 (construction cost for Phase 1 works is HK$39 million). Phases 2 and 3 include construction of a stormwater pumping station and an underground storage tank of 9,000 cu m capacity for discharging surface run-off collected at the low-lying area to the harbour, and a penstock to stop the back-flow of seawater (construction cost for Phases 2 and 3 is HK$ 200 million).
    [Show full text]
  • Off-Campus Attractions, Restaurants and Shopping
    Off-Campus Attractions, Restaurants and Shopping The places listed in this guide are within 30 – 35 minutes travel time via public transportation from HKU. The listing of malls and restaurants is suggested as a resource to visitors but does not reflect any endorsement of any particular establishment. Whilst every effort has been made to ensure the accuracy of the information, you may check the website of the restaurant or mall for the most updated information. For additional information on getting around using public transports in Hong Kong, enter the origin and destination into the website: http://hketransport.gov.hk/?l=1&slat=0&slon=0&elat=0&elon=0&llon=12709638.92104&llat=2547711.355213 1&lz=14 or . For more information on discovering Hong Kong, please visit http://www.discoverhongkong.com/us/index.jsp or . Please visit https://www.openrice.com/en/hongkong or for more information on food and restaurants in Hong Kong. Man Mo Temple Address: 124-126 Hollywood Road, Sheung Wan, Hong Kong Island How to get there: MTR Sheung Wan Station Exit A2 then walk along Hillier Street to Queen's Road Central. Then proceed up Ladder Street (next to Lok Ku Road) to Hollywood Road to the Man Mo Temple. Open hours: 08:00 am – 06:00 pm Built in 1847, is one of the oldest and the most famous temples in Hong Kong and this remains the largest Man Mo temple in Hong Kong. It is a favorite with parents who come to pray for good progress for their kids in their studies.
    [Show full text]
  • FORM 20-F Cootek
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR _ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report . Commission file number: 001-38665 CooTek (Cayman) Inc. (Exact Name of Registrant as Specified in Its Charter) N/A (Translation of Registrant’s Name Into English) Cayman Islands (Jurisdiction of Incorporation or Organization) Building 7, No. 2007 Hongmei Road, Xuhui District Shanghai, 201103 People’s Republic of China (Address of Principal Executive Offices) Jean Liqin Zhang, Chief Financial Officer Building 7, No. 2007 Hongmei Road, Xuhui District Shanghai, 201103 People’s Republic of China Phone: +86 21 6485-6352 Email: [email protected] (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange On Which Registered American depositary shares, each representing 50 Class A New York Stock Exchange ordinary share Class A ordinary shares, par value US$0.00001 per share* New York Stock Exchange* *Not for trading, but only in connection with the listing on the New York Stock Exchange of American depositary shares.
    [Show full text]
  • Corporate Venturing Report 2019
    Corporate Venturing 2019 Report SUMMIT@RSM All Rights Reserved. Copyright © 2019. Created by Joshua Eckblad, Academic Researcher at TiSEM in The Netherlands. 2 TABLE OF CONTENTS LEAD AUTHORS 03 Forewords Joshua G. Eckblad 06 All Investors In External Startups [email protected] 21 Corporate VC Investors https://www.corporateventuringresearch.org/ 38 Accelerator Investors CentER PhD Candidate, Department of Management 43 2018 Global Startup Fundraising Survey (Our Results) Tilburg School of Economics and Management (TiSEM) Tilburg University, The Netherlands 56 2019 Global Startup Fundraising Survey (Please Distribute) Dr. Tobias Gutmann [email protected] https://www.corporateventuringresearch.org/ LEGAL DISCLAIMER Post-Doctoral Researcher Dr. Ing. h.c. F. Porsche AG Chair of Strategic Management and Digital Entrepreneurship The information contained herein is for the prospects of specific companies. While HHL Leipzig Graduate School of Management, Germany general guidance on matters of interest, and every attempt has been made to ensure that intended for the personal use of the reader the information contained in this report has only. The analyses and conclusions are been obtained and arranged with due care, Christian Lindener based on publicly available information, Wayra is not responsible for any Pitchbook, CBInsights and information inaccuracies, errors or omissions contained [email protected] provided in the course of recent surveys in or relating to, this information. No Managing Director with a sample of startups and corporate information herein may be replicated Wayra Germany firms. without prior consent by Wayra. Wayra Germany GmbH (“Wayra”) accepts no Wayra Germany GmbH liability for any actions taken as response Kaufingerstraße 15 hereto.
    [Show full text]
  • When Is the Best Time to Go to Hong Kong?
    Page 1 of 98 Chris’ Copyrights @ 2011 When Is The Best Time To Go To Hong Kong? Winter Season (December - March) is the most relaxing and comfortable time to go to Hong Kong but besides the weather, there's little else to do since the "Sale Season" occurs during Summer. There are some sales during Christmas & Chinese New Year but 90% of the clothes are for winter. Hong Kong can get very foggy during winter, as such, visit to the Peak is a hit-or-miss affair. A foggy bird's eye view of HK isn't really nice. Summer Season (May - October) is similar to Manila's weather, very hot but moving around in Hong Kong can get extra uncomfortable because of the high humidity which gives the "sticky" feeling. Hong Kong's rainy season also falls on their summer, July & August has the highest rainfall count and the typhoons also arrive in these months. The Sale / Shopping Festival is from the start of July to the start of September. If the sky is clear, the view from the Peak is great. Avoid going to Hong Kong when there are large-scale exhibitions or ongoing tournaments like the Hong Kong Sevens Rugby Tournament because hotel prices will be significantly higher. CUSTOMS & DUTY FREE ALLOWANCES & RESTRICTIONS • Currency - No restrictions • Tobacco - 19 cigarettes or 1 cigar or 25 grams of other manufactured tobacco • Liquor - 1 bottle of wine or spirits • Perfume - 60ml of perfume & 250 ml of eau de toilette • Cameras - No restrictions • Film - Reasonable for personal use • Gifts - Reasonable amount • Agricultural Items - Refer to consulate Note: • If arriving from Macau, duty-free imports for Macau residents are limited to half the above cigarette, cigar & tobacco allowance • Aircraft crew & passengers in direct transit via Hong Kong are limited to 20 cigarettes or 57 grams of pipe tobacco.
    [Show full text]
  • Via on King Street, Unnamed Road, Tai Chung Kiu Road, Sha Tin Rural Committee Road and Tai Po Road
    L. S. NO. 2 TO GAZETTE NO. 50/2004L.N. 203 of 2004 B1965 Air-Conditioned New Territories Route No. 284 Ravana Garden—Sha Tin Central RAVANA GARDEN to SHA TIN CENTRAL: via On King Street, unnamed road, Tai Chung Kiu Road, Sha Tin Rural Committee Road and Tai Po Road. SHA TIN CENTRAL to RAVANA GARDEN: via Sha Tin Centre Street, Wang Pok Street, Yuen Wo Road, Sha Tin Rural Committee Road, Tai Chung Kiu Road and On King Street. Air-Conditioned New Territories Route No. 285 Bayshore Towers—Heng On (Circular) BAYSHORE TOWERS to HENG ON (CIRCULAR): via On Chun Street, On Yuen Street, Sai Sha Road, Ma On Shan Road, Kam Ying Road, Sai Sha Road, Hang Hong Street, Hang Kam Street, Heng On Bus Terminus, Hang Kam Street, Hang Hong Street, Ma On Shan Road, On Chiu Street and On Chun Street. Special trips are operated from the stop on Kam Ying Road outside Kam Lung Court to Heng On. Air-Conditioned New Territories Route No. 286M Ma On Shan Town Centre—Diamond Hill MTR Station (Circular) MA ON SHAN TOWN CENTRE to DIAMOND HILL MTR STATION (CIRCULAR): via Sai Sha Road, Hang Hong Street, Chung On Estate access road, Chung On Bus Terminus, Chung On Estate access road, Sai Sha Road, roundabout, Hang Fai Street, Ning Tai Road, Po Tai Street, Ning Tai Road, Hang Tai Road, Hang Shun Street, A Kung Kok Street, Shek Mun Interchange, *(Tate’s Cairn Highway), Tate’s Cairn Tunnel, Hammer Hill Road, roundabout, Fung Tak Road, Lung Poon Street, Diamond Hill MTR Station Bus Terminus, Lung Poon Street, Tai Hom Road, Tate’s Cairn Tunnel, Tate’s Cairn Highway, Shek Mun Interchange, A Kung Kok Street, Hang Shun Street, Hang Tai Road, Ning Tai Road, Hang Fai Street, roundabout, Sai Sha Road, On Yuen Street, On Chun Street, On Chiu Street and Sai Sha Road.
    [Show full text]
  • Shop 123, 1St Floor, Peninsula Centre, 67 Mody Road, Tsim Sha Tsui East, Kowloon
    NO NAME ADDRESS TELP FAX 1 A Maids Employment Services Centre Shop 123, 1st Floor, Peninsula Centre, 67 Mody Road, Tsim Sha Tsui East, Kowloon. 2111 3319 3102 9909 2 A.V.M.S Limited Shop L115, 1st floor, Metro Harbour Plaza, Tai Kok Tsui, Kowloon 3144 3367 3144 3962 3 Abadi Employment Consultant Centre Room 1108, 1st floor, Inciti Kar Shing Building, 15-19 Kau Yuk Road, Yuen Long, New Territories 3106 5716 3106 5717 4 ABNC Employment Agencies Co. Flat 79, Ground floor, Maximall, Blocks 1-3, City Garden, 233 Electric Road, North Point, Hong Kong. 25762911 25763600 5 Active Global Specialised Caregivers (HK) Pte Ltd. Unit 1703-04, 17th floor, Lucky Centre, 165-171 Wan Chai Road, Wan Chai, Hong Kong 3426 2909 3013 9815 6 Advance Court Overseas Employment Co. Shop 34B, Level 2, Waldorf Shopping Centre, Castle Peak Road, TMTL 194, Tuen Mun, New Territories 2458 1573 2452 6735 7 Advantage Consultant Co. Flat C, 12th FIoor, Kam Wah Building, 516 Nathan Road, Yau Ma Tei, Kowlon 26012708 27711420 8 AIE Employment Centre Room 1605, 16th floor, Hollywood Plaza, 610 Nathan Road, Mong Kok, Kowloon 2770 1198 2388 9057 9 Alim Prima Employment Agency Room K & L, 4th floor, Hennessy Apartments, 488 Hennessy Road, Causeway Bay, Hong Kong 25040629 27709803 10 All The Best Employment Limited. 1st floor, 92 Kam Tin Road, Yuen Long, New Territories 2807 0870 2807 0869 11 Allwin Employment Centre Limited Mezzanine floor, 408 Ma Tau Wau Road, Hung Hom, Kowloon 28668585 28669595 12 An Apple Travel & Employment Services Limited Room 907, 9th floor, Tower 2, Silvercord,
    [Show full text]
  • Q2 2018 Venture Capital Deals and Exits 3 July 2018
    DOWNLOAD THE DATA PACK Q2 2018 VENTURE CAPITAL DEALS AND EXITS 3 JULY 2018 Fig. 1: Global Quarterly Venture Capital Deals*, Fig. 3: Number of Venture Capital Deals in Q2 2018 by Q1 2013 - Q2 2018 Fig. 2: Venture Capital Deals* in Q2 2018 by Region Investment Stage 4,500 80 100% Angel/Seed 7% 5% 1% 3% 4,000 2% 70 Aggregate Deal Value ($bn) 90% 1% 6% 3% Series A/Round 1 Other 1% 3% 3,500 60 80% 4% Series B/Round 2 3,000 50 70% 31% Israel 6% 2,500 54% 36% Series C/Round 3 60% 40 India 2,000 Series D/Round 4 and 50% No. of Deals 30 1,500 17% Later Greater China Growth 40% 16% 1,000 20 8% Capital/Expansion Proportion of Total Europe PIPE 500 10 30% 0 0 20% 37% North America Grant 31% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 10% Venture Debt 30% 2013 2014 2015 2016 2017 2018 0% Add-on & Other No. of Deals Aggregate Deal Value ($bn) No. of Deals Aggregate Deal Value Source: Preqin Source: Preqin Source: Preqin Fig. 5: Average Value of Venture Capital Deals by Investment Fig. 4: Venture Capital Deals* in Q2 2018 by Industry Stage, 2016 - H1 2018 Fig. 6: Number of US Venture Capital Deals* in Q2 2018 by State 40% 37% 140 35% 120 115 117 104 30% 2016 100 California 25% 24% 23% 80 80 2017 20% 34% New York 36% 14% 15% 60 49 15% 13% 13% 41 Q1-Q2 12% Massachusetts 40 32 29 32 29 2018 Proportion Proportion of Total 9% 26 2828 28 10% 8% 16 22 5% 5% Average Deal Size ($mn) 20 1211 5% 4% 4% 4% Washington 2% 1% 3%2% 2% 2 2 2 0% 0 Illinois 4% Other Round 3 Round 1 Round 2 Series C/ Series Series A/ Series B/ Series 4% Internet Other IT Other Other Services Business Food & Related Telecoms 13% Angel/Seed Industrials Healthcare Agriculture Software & 9% Consumer Expansion Venture Debt Venture 4 and Later Discretionary Series D/Round Series Growth Capital/ No.
    [Show full text]
  • History, Development and Corporate Structure
    THIS DOCUMENT IS IN DRAFT FORM, INCOMPLETE AND SUBJECT TO CHANGE AND THE INFORMATION MUST BE READ IN CONJUNCTION WITH THE SECTION HEADED “WARNING” ON THE COVER OF THIS DOCUMENT HISTORY, DEVELOPMENT AND CORPORATE STRUCTURE OVERVIEW We are an innovative biopharmaceutical company focused on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. With a product portfolio covering full disease cycle and patient segmentations, our drug candidates address a unique spectrum of acute and chronic respiratory and lung diseases that currently lack effective treatments. As of the Latest Practicable Date, we had developed a pipeline of nine drug candidates, including a three-asset RSV franchise led by ziresovir, our Core Product and one of our lead assets, and a three-asset anti-fibrotic franchise highlighted by AK3280, our other lead asset. The history of our Group can be traced back to August 2013 when Dr. Wu founded ArkBio Cayman, the predecessor of our Company. Our Company was established in Shanghai as a limited liability company under the PRC Company Law in April 2014 by ArkBio Limited, which was wholly-owned by ArkBio Cayman, and was converted into a joint stock company on March 5, 2021. See “Directors, Supervisors and Senior Management” section in this document for the relevant industry experience of Dr. Wu. KEY MILESTONES The following is a summary of our Group’s key corporate and business development milestones. 2013 ArkBio Cayman was incorporated. 2014 Our Company was established. We in-licensed global rights of ziresovir (AK0529) from Roche. 2015 We completed series A financing.
    [Show full text]
  • NYC Healthcare Venture Capital Report
    2020 New York City Healthcare Venture Capital Report INTRODUCTION Welcome to the third annual New York City Healthcare Venture Capital Report. 2019 marked the ten-year anniversary of NYC Health We also explore key trends that are driving investment, Business Leaders (NYCHBL), during which we have seen interest and excitement including: a decade of incredible growth for NYC health start-ups. When Dr. Yin Ho and I co-founded NYCHBL in 2009, • LIFE SCIENCES. A decade ago, it was hard to name our goal was to build an organization that would help any biotechs calling NYC home. Today it’s a vastly connect people passionate about healthcare, because different story as you’ll learn from our dedicated section we believed that NYC should be at the center of on the sector’s growth. (See pages 16-19) healthcare innovation given our many assets. Ten years, • DIGITAL THERAPEUTICS. An emerging area that 55 events and 250 speakers later, New York City has in marries therapeutics with technology to drive better fact become the epicenter of tech-driven healthcare. It’s patient outcomes, digital therapeutics (DTx) are gaining rewarding that we’ve been able to play a part in the traction. As we hear from leaders in this exciting growth story. space, DTx are poised to change clinical practice The 2020 report reflects your overwhelming response, and alter the way healthcare is delivered in the future. inspiring feedback and thoughtful commentary to last (See pages 12-13) year’s report. There are more expert insights, observations • INVESTOR LANDSCAPE. Interest in investing and interviews from leading entrepreneurs, investors and in health has gone far beyond the names we have advisors.
    [Show full text]
  • Private Equity & Venture Capital
    VOLUME 13, ISSUE 6 ■ AUGUST 2017 alternative assets. intelligent data. PRIVATE EQUITY & VENTURE CAPITAL SPOTLIGHT THE GROWTH OF VENTURE IN THIS ISSUE CAPITAL IN ASIA 47% Venture capital transactions in Asia account for 47% of global deals in 2017 YTD – the most of any region – with FEATURE 3 51% of fund managers surveyed in H2 2017 noting an increase in appetite from Asia-based LPs. The Growth of Venture Capital in Asia Find out more on page 3 FEATURE 8 Fund Terms: Finding the Right Balance FUND TERMS: FINDING THE RIGHT INDUSTRY NEWS 12 BALANCE THE FACTS 48% ■ Luxembourg, Belgium 14 of LPs think that performance fees are a key issues when and The Netherlands it comes to aligned interests with GPs. How much of an ■ Sample Investors to 17 impact is this issue in reality, and what are GPs doing to Watch keep both parties happy? Find out more on page 8 CONFERENCES 19 All data in this newsletter can be downloaded to RECENTLY RELEASED: Excel for free THE 2017 2017 PREQIN PRIVATE PREQIN PRIVATE CAPITAL FUND TERMS ADVISOR CAPITAL FUND TERMS ADVISOR alternative assets. intelligent data Sign up to Spotlight, our free monthly newsletter, providing insights into Order Your Copy Download Sample Pages performance, investors, deals and fundraising, powered by Preqin data: SIGN UP Alt Credit Intelligence European and US Fund Services Awards: Best Data and Information Provider | Africa Global Funds Awards 2016: Best Research and Data Provider | The Queen’s Award for Enterprise: International Trade | HedgeWeek Global Awards: Best Global Hedge Fund Research Provider | CAIA Corporate Recognition Award www.preqin.com/contact| [email protected] SuperReturn Middle East 2017 22 - 24 October, Hilton Capital Grand, Abu Dhabi Past lessons.
    [Show full text]
  • Venture Capital Report
    Venture Capital Report China | 2 Q | 2018 VENTURE CAPITAL REPORT VENTURE CAPITAL REPORT The following report presents Dow Jones VentureSource’s quarterly findings for Chinese venture capital fundraising, investment, valuation, and liquidity. The included charts and graphs offer a comprehensive view of the trends currently affecting the venture capital market. Highlights for 2Q 2018 include: • China venture capital fundraising increased, both in capital raised and the number of funds; • Capital flowed into venture-backed Chinese companies reached a fresh record; • Amount collected through mergers and acquisitions (M&As) climbed significantly; • The transaction number via initial public offerings (IPOs) climbed, while the money raised declined. VENTURE CAPITAL REPORT 2 CHINESE VENTURE CAPITAL FUNDRAISING IMPROVED IN 2Q 2018 FUNDRAISING Chinese VC Fundraising (2015–2018) In 2Q 2018, 12 Chinese venture funds collected $2.53 billion. Based on multiple closings 25 $6.00 The capital raised is more than five times as many as the amount collected in the prior quarter, and the number of $5.00 funds is more than doubled. 20 In comparison to the same period last year, amount raised $4.00 increased by 5%, while deal number dropped by 20%. 15 $3.00 • Qiming Venture USD Fund VI LP was the largest Chinese venture fund in 2Q 2018, raising $935 million and 10 $2.00 representing a 37% of the total amount raised in venture capital funds during the quarter. 5 $1.00 0 $0.00 2Q'15 3Q'15 4Q'15 1Q'16 2Q'16 3Q'16 4Q'16 1Q'17 2Q'17 3Q'17 4Q'17 1Q'18 2Q'18 Amount
    [Show full text]